NICE backs Keytruda/Padcev combo for bladder cancer
Patients with muscle-invasive bladder cancer can now receive NHS treatment with MSD's Keytruda and Astellas' Padcev, given before and after surgery.
Newsletters and Deep Dive digital magazine
Patients with muscle-invasive bladder cancer can now receive NHS treatment with MSD's Keytruda and Astellas' Padcev, given before and after surgery.
As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.
A gene therapy for alpha-1 antitrypsin deficiency developed by China's YolTech has successfully treated a patient with a severe form of the disease.
A patient-led initiative for hereditary haemorrhagic telangiectasia (HHT) has won the inaugural Prix Galien Patient First Award.
A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.
Editor's Picks
Newsletters and Deep Dive
digital magazine